Panel
Advancing Precision Oncology: Prevention, Early Detection, & Treatment | Middle East & Africa Summit
- Precision oncology, tailored mutation-based treatments, and emerging technologies are projected to transform cancer from a deadly disease into a manageable chronic condition comparable to hypertension or diabetes by 2050.
- Survival rates for advanced lung cancer are expected to rise to 40–45% with current therapies and up to 85% for early detection cases, reflecting a shift from the 10–15% rates observed in the 1980s and 1990s.
- Artificial intelligence is predicted to become essential for processing 3.2 billion DNA sequence and epigenomic permutations to match specific therapies, accelerate drug development by identifying molecular targets, and shorten the translational gap from 17 years to a significantly reduced timeframe.
- Automated laboratory models, including tumor organoid testing and AI-linked automation, are expected to be operational within three to five years, potentially eliminating the need for some traditional lab drug tests while robots begin performing supervised surgical tasks.
- Surgical advancements utilizing immunofluorescence, MRI fusion, and "guardrails" are anticipated to enable robots to perform autonomous surgical components, while remote surgery capabilities are projected to see growth over the next five years.
- Prevention strategies, including metabolic risk management, GLP-1 drug repurposing, and risk scores combining genetic and metabolic data, are expected to reduce cancer rates and disease onset, with specific validation efforts planned in Abu Dhabi.
- Public-private partnerships are projected to accelerate clinical trial approvals from 36 months to approximately 18 months, and the Abu Dhabi operational model for colorectal cancer screening is expected to be replicated globally.
- Screening guidelines and risk stratification systems are expected to evolve to detect cancer earlier, including multi-cancer tests using methylation signatures, with interventions potentially targeting high-risk individuals as early as age 15 or 20.
- Advocacy groups plan to continue integrating digital health tools and engaging with government bodies like the Ministry of Health and Prevention to ensure patient perspectives shape policy and global platforms.
- A future methodology addressing the root causes of aging is expected to mechanistically prevent most cancers by 2050, while immunotherapy is anticipated to expand its role to treating chronic conditions such as diabetes and MS.